Edwards Lifesciences Corporation (NYSE:EW) announced one-year results from the CLASP IID trial and registry, confirming the safety and efficacy of its PASCAL system for treating degenerative mitral regurgitation (DMR). The trial showed a freedom from major adverse events rate of 84.7% at one year, and significant and sustained MR reduction, with 95.8% of patients achieving MR ≤2+ at one year. The PASCAL system also showed sustained outcomes of high survival, low heart failure hospitalization and meaningful quality-of-life improvements.